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ABSTRACT 
 
The management of patients with mesothelioma and thymic malignancy requires continuous 
multidisciplinary expertise at any step of the disease. A dramatic improvement in our 
knowledge has occurred in the last few years, through the development of databases, 
translational research programs, and clinical trials. Access to innovative strategies represents a 
major challenge, as there is a lack of funding for clinical research in rare cancers and their 
rarity precludes the design of robust clinical trials that could lead to specific approval of 
drugs. In this context, patient-centered initiatives, such as the establishment of dedicated 
networks, are warranted. International societies, such as IMIG (International Mesothelioma 
Interest Group) and ITMIG (International Thymic Malignancy Interest Group) provide 
infrastructure for global collaboration, and there are many advantages to having strong 
regional groups working on the same issues. There may be regional differences in risk factors, 
susceptibility, management and outcomes. The ability to address questions both regionally as 
well as globally is ideal to develop a full understanding of mesothelioma and thymic 
malignancies. 
In Europe, through the integration of national networks with EURACAN, the collaboration 
with academic societies and international groups, the development of networks in thoracic 
oncology provides multiplex integration of clinical care and research, ultimately ensuring 
equal access to high quality care to all patients, with the opportunity of conducting high level 
clinical and translational research projects. 
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INTRODUCTION 
 
Rare thoracic tumors are defined as tumors originating from the lung, the pleura, or the 
mediastinum with low incidence [www.RARECARE.eu] and unusual histology [1]. Overall, 
these tumors account for about 11% of all primary thoracic tumors, whereas they correspond 
to more than 100 different histologic, clinical, radiologic, and prognostic entities [2]. Thoracic 
rare tumors are characterized by limited clinical and imaging descriptions, by the low number 
of experienced specialists for each tumor subtype, and by the limited amount of specific 
therapeutic data [1].  
The recent establishment of the European Reference Network EURACAN provides an 
infrastructure of healthcare providers with high level of multidisciplinary expertise for the 
diagnosis, and the management and follow-up of patients with rare cancers, including rare 
thoracic tumors; the objective is to increase the quality of care, while building collaboration to 
develop clinical and translational research projects 
[www.ec.europa.eu/health/sites/health/files/ern/docs/erneuracan_factsheet_en.pdf]. 
Mesothelioma is the most frequent and thymic tumour is one of the rarest tumor types among 
rare thoracic cancers [2]; while patients have already been treated in dedicated networks in 
some European countries, initiatives have been taken at the European level to share clinical 
practices, analyze large databases, and develop common guidelines. However, at population 
level, hospital centralisation of rare cancer patients from seven different European countries, 
studied for the period 2000-2007 was not as expected, especially for patients with 
mesothelioma. The recently published study showed an annual mean admission hospital 
volume of 5 cases of mesothelioma, with a large variation across countries [2]. 
 
EPIDEMIOLOGICAL DATA 
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Mesothelioma 
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer that develops from the 
surface mesothelium of the pleural cavity [2]. In Europe (EU28), about 11.000 new cases are 
diagnosed in a year with a crude incidence of 1.8/100,000 individuals per year [2], 
representing 3% of all thoracic cancers. The prevalence estimated for the year 2008 was 
3/100,000 individuals, with 15,650 cases in EU28 [2]. 
This malignancy is strongly related to exposure to asbestos, and in fact more than 80% of 
cases is due to professional exposure [3].  
There is a long latency (30 to 50 years) between exposure and disease presentation and in fact 
the highest incidence is reported in patients aged over 65 (7.8 100,000). For this reason, 
although asbestos has been banned in 55 countries for at least the last 20 years, a peak in 
incidence is expected in 2020-2030 in Western countries [3]. Unfortunately, the continued use 
of asbestos in developing countries and the inefficient disposal of the asbestos used in the past 
for buildings in the industrialised countries could lead to a new wave of MPM diagnosis in 
extended areas [3].  
 
What about survival? 
Thoracic mesothelioma has a very poor prognosis. In Europe, during the period 2000-2007, 1- 
3- and 5-year survival was 39, 9 and 5%, respectively. Outcome was slightly better in young 
(25-64 years of age) than old patients (>65 years of age): at 3 years survival figure was 12% 
versus 7%. Survival was slightly better in females than males (3-year survival 12% versus 
8%). A low, but significant, progress was reported for 1-year survival: from 34% (1999-2001) 
to 40% (2005-2007) [2]. 
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Thymic malignancies 
Thymic malignancies are rare cancers. In Europe, the annual crude incidence rates ranging 
from <1 (Northern Ireland, Scotland, Iceland, Lithuania) and between 2 and 3.5 per million 
individuals (Austria, Belgium, Italy, Malta, Spain, Switzerland and the Netherland). 
[www.RARECARE.eu, 4]. In France, from the RYTHMIC data, incidence in 2015 was 
higher (3.4 per million individuals) [5]. Mean age at diagnosis is 50-60 years-old, but thymic 
malignancies may actually be diagnosed in children as well as in elderly patients [6]. There is 
no consistent gender predilection in thymomas overall, even if a slight female preponderance 
has been reported for type A, AB, and B1 subtypes in most studies.  
No environmental or infectious factors have been demonstrated so far to play a role in the 
pathogenesis of thymic epithelial tumors. Reports on development of thymoma after radiation, 
solid-organ transplantation and HIV infection are rare; differential diagnosis with thymic 
rebound hyperplasia may be discussed in this setting [7]. Genetic risk factors may participate 
in the development of thymomas, given rare occurrence in case of familial background or 
association with cancer susceptibility syndromes, such as MEN1. Moreover, extra-thymic 
haematopoietic and solid cancers have been reported to occur, before and after thymoma 
diagnosis, at increased frequency [8].  
Five-year survival of malignant epithelial tumours of thymus, as assessed for Europe for the 
period 2000-2007, was 64% [2], with large variation accross type of tumor.  The highest 
outcome (69%) was reported for malignant thymoma and the lowest (13%) for the 
undifferentiated cancer of thymus [www.RARECARE.eu]. 
 
CURRENT STRATEGIES FOR MESOTHELIOMA AND THYMIC TUMORS 
 
Mesothelioma 
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The histological diagnosis of MPM is often complex due to the heterogeneity of this group of 
tumors. The three main histological subtypes are the epithelioid type, which is the most 
common (50-70%) and usually has more favourable prognosis; the sarcomatoid type (10-
20%) that is the most aggressive; and the biphasic type (20-35%) that has both epithelial and 
sarcomatoid elements and has an intermediate prognosis [9]. Execution of biopsies is strongly 
advised in order to have a correct diagnosis that ideally should be performed by expert 
pathologist with the aim of reducing pitfall and diagnostic delays. Uncorrect diagnosis and in 
particular the inclusion of non-neoplastic lesions could explain the high survival for MPM in 
some European countries.  
Due to the rarity and the complexity of the disease, each case should be evaluated in a 
multidisciplinary team in expert centers, consisting of a surgeon, a medical oncologist, 
pulmonologist, pathologist, nurses, palliative care specialist. The treatment strategy includes 
surgery in some cases, and chemotherapy for the majority of patients.  
 
Surgery with radical intent may be offered to those patients with stage I-III disease, epithelial 
or biphasic histology and that are medically operable [10]. However, due to its location it is 
virtually impossible to obtain free resection margins, therefore the intent is often to remove all 
the visible tumor.  Main surgical procedures, as defined according to the International 
Association for the Study of Lung Cancer [11] include: 
- EPP (extrapleural pneumonectomy) that entails a complete en bloc removal of the involved 
pleura and the whole lung, sometimes extended to the diaphragm and pericardium; 
- P/D (pleurectomy/decortication) that implies the removal of all gross tumor;  
- Extended P/D that usually includes the resection of the diaphragm and pericardium if 
involved; 
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- Partial pleurectomy that implies the resection of part of the involved pleura, leaving gross 
tumor behind. 
The prospective randomized Mesothelioma and Radical Surgery 1 (MARS 1) trial enrolled 
patients, who were treated with induction chemotherapy and then randomized between EPP 
and no EPP. In the feasibility study, 112 patients were enrolled over a 3-year period. Only 
45% of patients (50/112) could be randomized after induction therapy, and 16 were randomly 
assigned to receive EPP. In this small group, mortality rate was 19% and median overall 
survival was 14 months, compared with 19 months for those not having EPP [12]. A 
subsequent trial was designed (MARS2) to assess the feasibility of randomization into P/D 
after induction chemotherapy (NCT02040272). Another trial with a similar design is ongoing 
in Italy (PASS trial) [www.meso.ospedale.al.it].   
The combination of induction chemotherapy, surgery and radiotherapy (trimodality treatment) 
was studied in several trials, with inconsistent results. In a systematic review performed on 16 
studies (including 5 prospective trials), median overall survival ranged from 13 to 47 months 
with acceptable perioperative mortality (0% to 12.5%) [13]. However, a large prospective 
phase II trials of induction chemotherapy and EPP with or without radiotherapy has failed to 
show benefit in terms of survival with relevant toxicities, including one death from radiation 
pneumonitis [14]. The use of preoperative radiotherapy before EPP is being investigated, and 
was proved to be feasible with potential prolonged survival [15, 16]. More prospective trials 
are needed in order to assess the real benefit of radiotherapy and trimodality treatment.  
For advanced MPM, systemic therapy should be offered to patients with good performance 
status (PS 0-2), medically inoperable or refusing surgery, or affected by stage IV disease or in 
sarcomatoid histology (any stage).  In this setting radiotherapy can be considered for 
palliation of pain or to prevent sub cutaneous metastasis that can occur after local procedures. 
Surgery can be considered for pleural effusion management.  
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The standard for systemic treatment is represented by a combination of a platinum compound 
and a folate antagonist (pemetrexed) after 2 randomized phase III trial showed a survival 
advantage for the combination cisplatin-pemetrexed (overall survival of 12.1 months), and 
cisplatin-raltitrexed (overall survival of 11.4 months), compared to cisplatin alone (9.3 and 
8.8 months, respectively) [17, 18]. In a recent randomized phase III trial, the combination of 
cisplatin-pemetrexed-bevacizumab was compared to cisplatin-pemetrexed, showing an 
increased overall survival by 2.7 months (18.8 vs. 16.1 months) with a slightly higher toxicity 
rate (71% vs 62% of patients) [19]. Other acceptable combinations for first line chemotherapy 
include carboplatin and pemetrexed, that was assessed in 3 different phase II trials (median 
overall survival of 12.7, 14.0, and 14.0 months, respectively) [20-22].  
Other options for patients include cisplatin-gemcitabine; for second-line treatment, single-
agent pemetrexed (if not administered in first line setting; or as rechallenge in patients who 
had a good response to first line therapy), vinorelbine, and gemcitabine are possible. 
Immunotherapy seems potentially active in MP . A checkpoint inhibitor, the anti-CTLA4 
antibody tremelimumab, had shown interesting disease control rates in preliminary studies, 
but the phase IIb trial with tremelimumab vs. best supportive care in second and further lines 
has failed to show any advantage in unselected patients [23]. Other studies are ongoing with 
anti-PD-1/PD-L1 inhibitors, as well as with immunogenic therapy with intrapleural viral 
vectors and autologous dendritic vaccines. Research is also focusing on mesothelin-targeted 
treatments, including amatuximab, and anetumab ravtansine, anti-mesothelin immunotoxins 
(SS1P), mesothelin tumour vaccine (CRS-207), and chimeric antigen receptor T-cell targeted 
to mesothelin [24].  
 
Thymic tumors 
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Thymic malignancies represent a heterogeneous group of cancers, which are classified 
according to the World Health Organization (WHO) histopathologic classification, that 
distinguishes thymomas from thymic carcinomas [25]; thymomas are further subdivided into 
different types (so-called A, AB, B1, B2, and B3) based upon the relative proportion of the 
non-tumoral lymphocytic component, and the resemblance to normal thymic architecture 
[25]. Thymic carcinomas are similar to their extra-thymic counterpart, the most frequent 
subtype being squamous cell carcinoma [25, 26]. Staging of thymic tumors is currently based 
on the Masaoka-Koga system [27], that will be replaced by a TNM-based system for the 8th 
Edition of the AJCC/UICC staging classification of tumors starting 2018 [28]; the TNM 
staging may help to better define the resectability of the tumor. 
The management of thymic epithelial tumors is a paradigm of cooperation between clinicians, 
surgeons, and pathologists from establishing the diagnosis to organizing the multimodal 
therapeutic strategy (Figure 1) [7].  
Surgery is the mainstay of the curative-intent treatment, as complete resection represents the 
most significantly favorable prognostic factor on overall survival [7, 29]. Standard approach 
is median sternotomy, which allows the wide opening of the mediastinum and both pleural 
cavities. Generally, complete thymectomy including the tumor, the residual thymus gland and 
perithymic fat is preferred; if the tumor is widely invasive, en-bloc removal of all affected 
structures, including lung parenchyma (usually through limited resection), pericardium, great 
vessels, nerves and pleural implants, should be carried out. Minimally-invasive surgery is an 
option for small tumors in the hands of appropriately-trained thoracic surgeons.  
Radiotherapy may be delivered in the postoperative setting, aiming at reducing the risk of 
recurrence [7]. Stage and completeness of resection are thus the most relevant criteria in the 
decision-making, followed by histology.  
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Systemic treatment may be delivered in a curative-intent approach, for patients presenting 
with locally-advanced tumor at time of diagnosis, with invasion of intra-thoracic neighboring 
structures, and/or dissemination to the pleura and the pericardium, precluding upfront 
complete resection to be achieved. In such cases, chemotherapy has been used both to reduce 
the tumor burden - possibly allowing subsequent surgery and/or radiotherapy- and to achieve 
prolonged disease control [7, 30]. In this setting, cisplatin-based combination regimens should 
be administered; combinations of cisplatin, adriamycin, and cyclophosphamide, and cisplatin 
and etoposide have been recommended, based on historical studies [7, 31]. 
When the patient is not deemed to be a surgical candidate - either because R0 resection is not 
thought to be achievable, or because of poor performance status or co-existent medical 
condition, definitive radiotherapy is recommended part of a sequential chemoradiotherapy 
strategy [7]. Combination with chemotherapy (including cisplatin, etoposide chemotherapy 
and a total dose of radiation of 60 Gy) may be considered as well. 
Chemotherapy is also a palliative-intent treatment of unresectable, metastatic, and recurrent 
tumors, which are more frequently thymic carcinomas than thymomas [7, 29-31]. Again, 
cisplatin-based combination regimens with anthracyclins and/or etoposide are standard. No 
randomized studies have been conducted, and it is unclear which regimens are best; multi-
agent combination regimens and anthracycline-based regimens appear to have improved 
response rates compared to others, especially the etoposide, ifosfamide and cisplatin 
combination [7, 29-31]. Combination of carboplatin and paclitaxel is an option for thymic 
carcinoma, based on results of recent phase II trials [7].  
Recurrences of thymic epithelial tumors should be managed according to the same strategy as 
newly diagnosed tumors. Complete resection of recurrent lesions represents a major predictor 
of favorable outcome, and surgery is then recommended in case of resectable lesion [7]. In 
non-resectable recurrences, several consecutive lines of chemotherapy may be administered 
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when the patient presents with tumor progression. Preferred regimens for second-line 
treatment include carboplatin plus paclitaxel, and platin plus etoposide; capecitabine plus 
gemcitabine is an option [7, 29-31]. Options for subsequent lines include pemetrexed, oral 
etoposide.  
In the setting of advanced disease, multiple novel agents have been evaluated in thymic 
malignancies, with variable outcome. Sunitinib is an off-label option in the second-line 
setting, based on its antiangiogenic activity. Everolimus may be another option for refractory 
disease. Several trials assessing the efficacy of PD-1 checkpoint inhibitors are currently 
ongoing. Phase II studies of pembrolizumab were recently reported, collectively enrolling 63 
patients, showing response rates of 24%, but occurrence of serious, autoimmune adverse 
events in 20% to 30% of patients [32, 33]. The off-label use of checkpoint inhibitors is 
currently not recommended. 
 
NETWORKS 
 
The management of patients with mesothelioma and thymic malignancy requires continuous 
multidisciplinary expertise at any step of the disease. A dramatic improvement in our 
knowledge has occurred in the last few years, through the development of large databases, 
translational research programs, and clinical trials [34-38]. Access to innovative strategies 
represents a major challenge, as there is a lack of funding for clinical research in rare cancers 
and their rarity precludes the design of robust clinical trials  that could lead to specific 
approval of drugs. In this context, patient-centered initiatives, such as the establishment of 
dedicated networks, are warranted. International societies, such as IMIG (International 
Mesothelioma Interest Group) and ITMIG (International Thymic Malignancy Interest Group) 
provide infrastructure for global collaboration, and there are many advantages to having 
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strong regional groups working on the same issues [34-38]. There may be regional differences 
in risk factors, susceptibility, management and outcomes. The ability to address questions 
both regionally as well as globally is ideal to develop a full understanding of mesothelioma 
and thymic malignancies. Actually, diversity makes research in all the fields above discussed, 
more valuable. 
 
National Networks 
In France, RYTHMIC (Réseau tumeurs THYMiques et Cancer; www.rythmic.org) is a 
nationwide network for thymic malignancies, which was appointed in 2012 by the French 
National Cancer Institute, as part of its rare cancer program (Figure 2) [38]. Since then, the 
management of all patients diagnosed with thymic tumors has been discussed on a bi-mensual 
basis at a national multidisciplinary tumor board (MTB), which is organized twice a month 
basis using a web-based conferencing system. Decision-making is based on consensual 
recommendations, that were originally established based on available evidence, and are 
updated and approved each year by all members of the network. A prospective database of all 
patients is hosted by the French Thoracic Cancer Intergroup. Overall, more than 2,000 
patients have been enrolled, demonstrating the feasibility of a national MTB for thymic 
malignancies, that, besides ensuring patients an equal access to highly specialized 
management, provides with a comprehensive tool to monitor dedicated actions to improve the 
management of patients, and enroll patients in clinical trials. Similar thymoma-dedicated and 
mesothelioma-dedicated networks are now being implemented in France [www.e-
cancer.fr/content/.../file/Resaux-nationaux-cancers-rares-adultes-2015.pdf]. 
 and in other European countries, such as Spain and Italy (the TYME collaborative group) 
[39, 40]. 
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Outside Europe, The Chinese Alliance for Research in Thymomas (ChART) and the Japanese 
Association for Research on the Thymus (JART) are national groups aiming at building and 
analyzing retrospective and prospective databases of thymic tumors cases [36, 37].  
 
International networks 
The International Thymic Malignancies Interest Group (www.itmig. org) was created in 2010, 
and was endorsed and supported by the most representative medical and surgical societies 
around the globe [35]. The mission of ITMIG is to promote the advancement of clinical and 
basic science related to thymic malignancies. It provides infrastructure for international 
cooperation, trials, maintains close collaboration with other related organizations, and 
facilitates the spread of knowledge about thymic neoplasms. The achievements of ITMIG 
include 1)the development of standard definitions based on multidisciplinary consensus, 
regarding outcome measures, handling of surgical specimens, staging, surgical techniques, 
radiotherapy, and chemotherapy; 2) a significant contribution to the WHO histopathological 
classification update; and 3/ the establishment of an international, retrospective database of 
nearly 10,000 cases that has been a resource for descriptive studies, mostly driven by US-
based investigators,  as well as for the development of the 2018 TNM-based staging system as 
a backbone for the survival analyses of specific groups of patients [28]. A prospective 
database linked to a virtual tumor bank is underway. 
The International Mesothelioma Interest Group was created in the early 90’, aiming at holding 
an international mesothelioma conference on alternate years, improving collaboration by 
generating a list of available research resources, and fostering international interest groups to 
address specific issues of importance, e.g. early diagnosis, thoracoscopy, comparison of 
national mesothelioma registers.  
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European Networks 
Research on mesothelioma and thymic malignancies has historically been driven by thoracic 
surgery societies, including the European Society of Thoracic Surgery (ESTS) and the 
European Association of Cardio-thoracic Surgeons (EACTS) for thymic tumours; especially, 
the ESTS published multiple analyses on a retrospective cohort of patients [44], and is 
currently establishing a prospective database.  
The European Society for Medical Oncology recently published the first multidisciplinary, 
comprehensive clinical practice guidelines for the management of mesothelioma and thymic 
tumors, integrating all the aspects of the management of the disease, from the diagnosis to the 
follow-up of patients [7, 10]; as shown on Figure 3, the level of evidence of thymic tumors 
recommendations is far lower than that of guidelines for non-small cell lung cancer and 
mesothelioma.  
Within the European Reference Network EURACAN, the rare thoracic tumor domain – 
referred as to G8 domain - handles a network of 20+ healthcare providers; the objectives of 
EURACAN include the updating and the assessment of current guidelines, the development 
of educational programs, dissemination and communication with patients groups, and the 
establishment of research projects, from the diagnosis workup of the disease to the therapeutic 
strategies. Achieving the highest quality of patient care is the main objective of EURACAN, 
and the RYTHMIC model provides some practical tools to be implemented at the European 
level. The European network also provides an infrastructure for collaboration with diagnosis 
and pharmaceutical companies; one example may be the opening of dedicated cohorts in 
basket studies assessing new drugs, for which the network allows a better identification of 
patients and facilitates the recruitment in the trials [clinicaltrials.gov NCT03012620].  
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In Europe, through the integration of national networks with EURACAN, the collaboration 
with academic societies and international groups, the development of networks in thoracic 
oncology provides multiplex integration of clinical care and research, with the opportunity of 
conducting high level clinical and translational research projects, and ultimately ensuring 
equal access to high quality care to all patients. Within EURACAN the evaluation of outcome 
will be based on the use of cancer registry population data, the integration with clinical 
databases will be crucial to understand the extent of the access to standard treatment and to 
reduce the disparities. 
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FIGURES LEGENDS 
 
 
Figure 1: Management strategies for thymic tumors. 
 
 
Figure 2: Infrastructure of the French RYTHMIC network. Legends: CME: Continuous 
Medical Education 
 
 
Figure 3: Levels of evidence in the clinical practice guidelines of the European Society for 
Medical Oncology for non-small cell lung cancer, mesothelioma, and thymic tumors. Legend: 
NSCLC: non-small cell lung cancer 
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